CN112105390A - 用于提高物理稳定性和增强抗肿瘤功效的胶束中低聚乳酸缀合物的立体复合物 - Google Patents

用于提高物理稳定性和增强抗肿瘤功效的胶束中低聚乳酸缀合物的立体复合物 Download PDF

Info

Publication number
CN112105390A
CN112105390A CN201980031778.XA CN201980031778A CN112105390A CN 112105390 A CN112105390 A CN 112105390A CN 201980031778 A CN201980031778 A CN 201980031778A CN 112105390 A CN112105390 A CN 112105390A
Authority
CN
China
Prior art keywords
lactic acid
gemcitabine
oligo
gem
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980031778.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·S·权
Y·T·谭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CN112105390A publication Critical patent/CN112105390A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980031778.XA 2018-04-02 2019-04-01 用于提高物理稳定性和增强抗肿瘤功效的胶束中低聚乳酸缀合物的立体复合物 Pending CN112105390A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651365P 2018-04-02 2018-04-02
US62/651,365 2018-04-02
PCT/US2019/025174 WO2019195164A1 (en) 2018-04-02 2019-04-01 Stereocomplex of oligolactic acid conjugates in micelles for improved physical stability and enhanced antitumor efficacy

Publications (1)

Publication Number Publication Date
CN112105390A true CN112105390A (zh) 2020-12-18

Family

ID=66175512

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980031778.XA Pending CN112105390A (zh) 2018-04-02 2019-04-01 用于提高物理稳定性和增强抗肿瘤功效的胶束中低聚乳酸缀合物的立体复合物

Country Status (6)

Country Link
US (2) US20210128736A1 (https=)
JP (1) JP7495352B2 (https=)
KR (1) KR20200139737A (https=)
CN (1) CN112105390A (https=)
CA (1) CA3095788A1 (https=)
WO (1) WO2019195164A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110652595B (zh) * 2019-10-21 2022-11-29 南通大学附属医院 一种聚亮氨酸-聚天冬氨酸嵌段共聚物立构复合载药胶束及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599073A (zh) * 2013-11-15 2014-02-26 无锡中科光远生物材料有限公司 一种负载有靶向抗癌药物的plga微米颗粒的制备方法
CN104961786A (zh) * 2015-06-05 2015-10-07 苏州大学 基于吉西他滨结构的前体药物及其应用
WO2017158499A1 (en) * 2016-03-14 2017-09-21 Wisconsin Alumni Research Foundation Oligolactic acid conjugates and micelles with enhanced anticancer efficacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
JP5048690B2 (ja) * 2006-03-08 2012-10-17 クローズ 特に種子発芽および植物発生のための遅延性効果の農業処理剤
US8668919B2 (en) * 2009-03-03 2014-03-11 Abbott Cardiovascular Systems Inc. Polymer for creating hemocompatible surface
WO2017201407A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel particle of cystamine cross-linked dextran aldehyde containing imine conjugated doxorubicin and rgd peptide for chemotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599073A (zh) * 2013-11-15 2014-02-26 无锡中科光远生物材料有限公司 一种负载有靶向抗癌药物的plga微米颗粒的制备方法
CN104961786A (zh) * 2015-06-05 2015-10-07 苏州大学 基于吉西他滨结构的前体药物及其应用
WO2017158499A1 (en) * 2016-03-14 2017-09-21 Wisconsin Alumni Research Foundation Oligolactic acid conjugates and micelles with enhanced anticancer efficacy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERTIN, A 等: "Emergence of Polymer Stereocomplexes for Biomedical Applications" *
DAMAN, Z等: "Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: A comparison with its self-assembled nanoparticles" *

Also Published As

Publication number Publication date
US20240207416A1 (en) 2024-06-27
JP2021520344A (ja) 2021-08-19
US20210128736A1 (en) 2021-05-06
KR20200139737A (ko) 2020-12-14
JP7495352B2 (ja) 2024-06-04
WO2019195164A1 (en) 2019-10-10
CA3095788A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
US12534571B2 (en) Amphiphilic block copolymer, preparation method thereof and nanomicelle drug-loading system
EP2913353B1 (en) Amphiphilic block copolymer and preparation method thereof and micellar drug-loading system formed by same with antitumor drug
JP5544357B2 (ja) 水酸基を有する生理活性物質の高分子結合体
US10980891B2 (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
CN1761485B (zh) 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂
CN101489592A (zh) 考布他汀的高分子量偶联物
US20240207416A1 (en) Stereocomplex of oligolactic acid conjugates in micelles for improved physical stability and enhanced antitumor efficacy
TWI694838B (zh) 用於疏水性藥物傳送的新穎以聚合物爲基礎的增溶物
HK40002729A (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
HK40035098A (en) Amphiphilic block copolymer, preparation method thereof and nanomicelle drug-loading system
HK40035098B (en) Amphiphilic block copolymer, preparation method thereof and nanomicelle drug-loading system

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination